Reducing Attack Frequency: Preventive Treatment Options
At a Glance
Preventive treatment can reduce how often, how severely, and how long migraine without aura attacks last. Options now include CGRP-targeted medicines as first-line choices, traditional pills, and Botox for chronic migraine; the best option depends on attack frequency, other health conditions, safety, and preferences.
If your migraine attacks are frequent, severe, or making it hard to live your life, it may be time to move beyond stopping individual attacks and start preventive treatment. The goal of prevention is not necessarily to eliminate every migraine but to “lower the volume” of the disease—reducing the frequency, severity, and duration of attacks while improving your responsiveness to acute medications [1][2].
When to Start Prevention
Neurologists generally suggest considering preventive therapy if you experience [2][3]:
- About four migraine days per month or fewer when attacks are disabling, acute treatments fail or are contraindicated. (A migraine day involves migraine features or successful early treatment; a headache day is any non-migraine head pain).
- Attacks that significantly interfere with your work or social life despite using acute treatments.
- A risk of Medication Overuse Headache because you are using acute drugs too often.
A New Standard: 2024 AHS Guidelines
For years, patients were required to “fail” older, cheaper medications before they could try newer, migraine-specific treatments. However, a major 2024 U.S. position statement from the American Headache Society (AHS) has changed this [4].
Current guidelines now elevate CGRP-targeted therapies—including monoclonal antibodies (like erenumab, fremanezumab, and galcanezumab) and gepants (like atogepant and rimegepant)—to first-line options [4]. This means you and your doctor can choose these newer treatments from the very beginning, alongside traditional oral medications, based on your personal health needs and preferences, though regulatory approval, cost, and insurance step-therapy requirements vary by country and plan [4][5].
First-Line Preventive Options
Because migraine is a systemic disorder, different medications work on different “switches” in the nervous system.
CGRP-Targeted Therapies
These are the first treatments designed specifically for migraine biology.
- Monoclonal Antibodies (mAbs): These are usually given as a self-injection once a month or as an IV infusion every three months, depending on the product [4][6].
- Gepants: These are oral pills. Dosing and schedules vary: atogepant is generally taken once daily for prevention, whereas rimegepant is generally taken every other day for prevention [7].
- The Advantage: These treatments often have fewer “off-target” side effects than older drugs for many individuals [6]. In real-world studies, more people stay on these treatments long-term compared to oral pills, though cost and access remain factors [8].
- The Risks: Common side effects include injection-site reactions, constipation, and occasionally a transient rise in blood pressure [9][10]. Human safety data for CGRP therapies in pregnancy are limited; they are generally not initiated or are discontinued in pregnancy, so discuss preconception counseling with your clinician.
Traditional Oral Preventives
These older medications were originally designed for other conditions (like high blood pressure or epilepsy) but were found to be effective for migraine.
- Beta-blockers (e.g., Propranolol): Often used if you also have high blood pressure or anxiety [11].
- Topiramate: This is a common choice but carries a higher risk of side effects, including “brain fog” (cognitive slowing), tingling in the hands or feet, and taste changes [12][13].
- Safety Warning: Topiramate carries important fetal risks and is contraindicated for migraine prevention in some jurisdictions. Tell your clinician if you are pregnant, planning to become pregnant, or breastfeeding. Do not abruptly start, stop, or change a preventive medication without your prescriber.
Chronic Migraine and Botox
The strategy for prevention changes if your condition has progressed to chronic migraine. This is defined as having a headache on at least 15 days per month for at least three months, where at least 8 of those days are migraines [14].
- OnabotulinumtoxinA (Botox): This is specifically indicated for chronic migraine [15]. It is not usually recommended for “episodic” migraine (fewer than 15 days a month) [14].
- The Procedure: Botox involves 31 to 39 small injections across the head and neck muscles every 12 weeks [16][17].
- The Efficacy: It can take two or three treatment cycles (6 to 9 months) to feel the full benefit [16][18]. Common side effects include temporary neck pain or a “droopy” eyelid [19].
Choosing Your Path
There is no single “best” preventive; the right choice depends on your “comorbidities”—other health conditions you may have [4]. For example, if you have insomnia, an antidepressant like amitriptyline might help both your sleep and your migraines. If you have cardiovascular disease, CGRP-targeted agents are often preferred because they do not constrict blood vessels like some other options [20][21].
Most preventives take time to show their full effect—some CGRP options work faster, but a typical trial is 8 to 12 weeks. Work with your doctor to judge success by looking at migraine days, total headache days, disability, and acute-medication use [4][18].
Common questions in this guide
When should I consider preventive treatment for migraine without aura?
Can a CGRP medicine be my first preventive migraine treatment?
What is the difference between CGRP injections and preventive migraine pills?
Is Botox an option if I do not have headaches every day?
How long should I try a migraine preventive before deciding whether it works?
What side effects can preventive migraine medicines cause?
How do I choose the best preventive treatment for my migraine attacks?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on the 2024 AHS guidelines, am I a candidate for starting a CGRP-targeted therapy as my very first preventive medication?
- 2.If we choose topiramate, what signs of cognitive 'brain fog' or sensory changes should I watch for, and when should we consider switching?
- 3.Given that I have fewer than 15 headache days a month, is Botox an option for me, or are we limited to oral and CGRP-targeted treatments?
- 4.How long of a trial do you recommend for a new preventive—such as two or three months—before we decide if it is working?
- 5.Are there specific health factors in my history, like high blood pressure or asthma, that make a beta-blocker or a CGRP antibody a better fit for me?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (21)
- 1
[Education for medication overuse headache : Results of a systematic literature review].
Diener HC, Graf M, Löhr H, Kropp P
Schmerz (Berlin, Germany) 2025; doi:10.1007/s00482-025-00891-9.
PMID: 40531323 - 2
From transformation to chronification of migraine: pathophysiological and clinical aspects.
Torres-Ferrús M, Ursitti F, Alpuente A, et al.
The journal of headache and pain 2020; (21(1)):42 doi:10.1186/s10194-020-01111-8.
PMID: 32349653 - 3
Headache and migraine: a leading cause of absenteeism.
Baigi K, Stewart WF
Handbook of clinical neurology 2015; (131()):447-63.
PMID: 26563803 - 4
Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC, Digre KB, Goadsby PJ, et al.
Headache 2024; (64(4)):333-341 doi:10.1111/head.14692.
PMID: 38466028 - 5
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
Ailani J, Burch RC, Robbins MS,
Headache 2021; (61(7)):1021-1039 doi:10.1111/head.14153.
PMID: 34160823 - 6
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.
Cohen F, Yuan H, DePoy EMG, Silberstein SD
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):922-930 doi:10.1007/s13311-022-01230-x.
PMID: 35426060 - 7
Drugs for Migraine Prophylaxis.
Diener HC, Grans J, Reuter U
Deutsches Arzteblatt international 2026; (123(5)):119-126.
PMID: 41572863 - 8
Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review.
Ray R, Virk GS, Regmi N, et al.
Cureus 2025; (17(8)):e91347 doi:10.7759/cureus.91347.
PMID: 41035604 - 9
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A, Vaughn C, Rayhill M
Headache 2020; (60(10)):2454-2462 doi:10.1111/head.13956.
PMID: 32969035 - 10
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review.
Naghdi S, Underwood M, Brown A, et al.
BMJ neurology open 2024; (6(1)):e000616 doi:10.1136/bmjno-2023-000616.
PMID: 38646505 - 11
2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.
Sico JJ, Antonovich NM, Ballard-Hernandez J, et al.
Annals of internal medicine 2024; (177(12)):1675-1694 doi:10.7326/ANNALS-24-00551.
PMID: 39467289 - 12
Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Damen JAA, Yang B, Idema DL, et al.
Annals of internal medicine 2025; (178(3)):369-380 doi:10.7326/ANNALS-24-00315.
PMID: 39899873 - 13
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH, Raffaelli B, Mecklenburg J, et al.
CNS drugs 2021; (35(8)):805-820 doi:10.1007/s40263-021-00834-9.
PMID: 34272688 - 14
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
Winner PK, Blumenfeld AM, Eross EJ, et al.
Drug safety 2019; (42(8)):1013-1024 doi:10.1007/s40264-019-00824-3.
PMID: 31102144 - 15
Botulinum toxins for the prevention of migraine in adults.
Herd CP, Tomlinson CL, Rick C, et al.
The Cochrane database of systematic reviews 2018; (6()):CD011616 doi:10.1002/14651858.CD011616.pub2.
PMID: 29939406 - 16
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
Bendtsen L, Sacco S, Ashina M, et al.
The journal of headache and pain 2018; (19(1)):91 doi:10.1186/s10194-018-0921-8.
PMID: 30259200 - 17
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM, Stark RJ, Freeman MC, et al.
The journal of headache and pain 2018; (19(1)):13 doi:10.1186/s10194-018-0840-8.
PMID: 29404713 - 18
OnabotulinumtoxinA injection in the treatment of chronic migraine.
Wang YF
Progress in brain research 2020; (255()):171-206 doi:10.1016/bs.pbr.2020.05.013.
PMID: 33008506 - 19
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F, Gaul C, García-Moncó JC, et al.
The journal of headache and pain 2019; (20(1)):26 doi:10.1186/s10194-019-0976-1.
PMID: 30845917 - 20
Migraine treatment: Position paper of the French Headache Society.
Moisset X, Demarquay G, de Gaalon S, et al.
Revue neurologique 2024; (180(10)):1087-1099 doi:10.1016/j.neurol.2024.09.008.
PMID: 39406556 - 21
Migraine across the menopausal transition and beyond: A narrative review.
Korn TF, Bernstein C
Headache 2026; (66(6)):1390-1404 doi:10.1111/head.70071.
PMID: 41934093
This page is for informational purposes only and does not constitute medical advice about choosing migraine prevention. Discuss your medical history, pregnancy plans, and medication options with your neurologist or another clinician.
Get notified when new evidence is published on migraine without aura.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.